NASDAQ$ALKS

Alkermes plc · Q3 2020 earnings

Q3 2020 earnings · · Investor relations

Briefing

Alkermes reported strong commercial execution and disciplined expense management in Q3 2020, leading to raised financial expectations for the year.

Alkermes plc reported Q3 2020 financial results with total revenues of $265.0 million. The company reported a GAAP net loss per share of $0.00 and non-GAAP earnings per share of $0.26. Strong commercial execution and disciplined expense management led to raised financial expectations for 2020.

  • Total revenues for the quarter were $265.0 million, compared to $255.2 million for the same period in the prior year.
  • GAAP net loss was $0.1 million for the quarter, or a GAAP net loss per share of $0.00, compared to a GAAP net loss of $52.9 million, or a GAAP net loss per share of $0.34, for the same period in the prior year.
  • Non-GAAP net income was $41.5 million for the quarter, or a non-GAAP basic and diluted earnings per share of $0.26, compared to a non-GAAP net loss of $7.0 million, or a non-GAAP basic and diluted loss per share of $0.04, for the same period in the prior year.
  • Net sales of ARISTADA were $62.4 million, reflecting a 16% year-over-year growth.

Headline financials

Total Revenue

$265M

Previous: $255M+3.8%
EPS (adj)

$0.26

Previous: -$0.04+750.0%
Capital Expenditures

-$36.8M

Previous: -$59M+37.6%
Free Cash Flow

-$36.9M

Previous: -$112M+67.0%
Net Income

-$134K

Previous: -$52.9M+99.7%
Operating Income

-$10.7M

Previous: -$53.6M+80.1%
Gross Profit

$222M

Previous: $213M+4.2%
Cash & Equivalents

$241M

Previous: $261M-7.9%
Total Assets

$1.88B

Previous: $1.76B+6.8%

Revenue & EPS history

Alkermes · Revenue · Quarterly

$265M

Q3 2020+3.8%vs Q3 2019
Beat estimate in 12 of 16 quarters(75%)
ActualEstimate

Revenue by segment

Alkermes · $143M total across 2 segments · Q3 2020

  • VIVITROL
    $80.3M-5.8%
  • ARISTADA
    $62.4M+16.4%

Forward guidance

Alkermes raised its financial guidance for 2020, expecting total revenue between $1.01 billion and $1.035 billion and non-GAAP net income between $50 million and $70 million.

Tailwinds

  • Total Revenue: $1,010 - $1,035 million
  • VIVITROL Net Sales: $305 - $315 million
  • ARISTADA Net Sales: $230 - $240 million
  • Other Income, Net: ~$30 million
  • Non-GAAP Net Income: $50 - $70 million

Headwinds

  • Cost of Goods Sold: $180 - $190 million
  • R&D Expenses: $375 - $390 million
  • SG&A Expenses: $530 - $545 million
  • Amortization of Intangible Assets: ~$40 million
  • GAAP Net Loss: ($95) - ($115) million

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q3 2020

Historical avgQ3 2020

-0.6%

Avg return

Earnings day

-0.0%

Avg return

5 days after

-0.5%

Avg return

30 days after

45%

27 / 60 earnings

Positive

+16.6%

Q4 2017

Best reaction

-14.8%

Q1 2020

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+6.2%+2.5%+27.0%
Q4 2025-6.6%-9.4%-12.0%
Q3 2025+3.9%+3.3%+0.0%
Q1 2025+6.3%+5.5%+6.4%
Q4 2024+4.8%+12.3%+6.5%
Q3 2024-6.3%-5.1%+3.3%
Q2 2024+12.2%+11.7%+11.8%
Q1 2024-2.8%-1.8%-4.6%
Q4 2023+15.0%+8.6%+2.7%
Q3 2023-2.4%-4.0%-3.7%
Q2 2023-1.8%-5.1%-11.9%
Q1 2023-7.1%-6.1%-3.9%
Q4 2022+4.0%+2.9%-3.6%
Q3 2022+3.8%+0.3%+12.2%
Q2 2022-9.7%-14.4%-16.5%
Q1 2022+9.8%+6.4%+12.5%
Q4 2021+8.8%+7.6%+12.1%
Q3 2021-8.2%-5.0%-28.7%
Q2 2021+5.9%+11.6%+28.9%
Q1 2021-3.2%-1.6%+0.8%
Q4 2020-11.8%-13.7%-15.3%
Q3 2020+5.6%+5.9%+20.2%
Q2 2020-8.8%-7.4%-19.0%
Q1 2020-14.8%-14.7%+1.6%
Q4 2019-7.0%-7.8%-15.5%
Q3 2019+5.7%+6.0%+13.9%
Q2 2019-10.2%+1.2%-12.3%
Q1 2019-12.2%-12.7%-31.1%
Q4 2018-1.2%+3.6%+3.3%
Q3 2018+3.0%+6.5%-11.6%
Q2 2018-0.1%-0.3%+2.0%
Q1 2018+1.5%+1.4%+3.9%
Q4 2017+16.6%+23.0%+12.0%
Q3 2017+0.7%-1.5%+3.2%
Q2 2017-4.1%-5.4%-12.4%
Q1 2017+2.0%+2.4%+1.0%
Q4 2016-2.9%-4.6%+3.7%
Q3 2016-1.4%+4.0%+8.4%
Q2 2016-3.6%-6.0%-14.1%
Q1 2016-2.0%
Q4 2015-1.4%
Q3 2015+7.6%
Q2 2015+2.4%
Q1 2015+3.1%
Q4 2014-3.4%
Q3 2014+7.7%
Q2 2014-7.2%
Q1 2014+3.2%
Q4 2013-7.7%
Q3 2013-3.7%
Q2 2013+3.5%
Q1 2013+3.9%
Q4 2010-1.0%
Q4 2012-9.9%
Q3 2012+2.2%
Q3 2011+2.2%
Q2 2011-7.7%
Q2 2012-7.7%
Q4 2011-7.7%
Q2 2010-3.0%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro